ONO-2506PO is currently undergoing a Phase II multi-centre extension study to evaluate its long-term safety in ALS patients. Given the increasing prevalence of ALS and the limited treatment options available, this study positions Ono Pharmaceutical Co., Ltd. to potentially capture a significant share of the ALS market if ONO-2506PO demonstrates favorable safety and efficacy profiles. The competitive landscape includes existing therapies such as Riluzole and Edaravone, but there remains a substantial unmet need for novel treatments. Diligence should focus on the outcomes of this study and any potential regulatory pathways that may expedite approval.